Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.52 |
| ▸ | FPR1 | P21462 | 7/20 | 0.52 |
| ▸ | F10 | P00742 | 8/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77517 | 0.85 | F10 (0.62) | FPR2FPR1F10MAPTSMN1; SMN2 | |
| SCHEMBL8271158 | 0.85 | F10 (0.62) | FPR2FPR1F10MAPTSMN1; SMN2 | |
| SCHEMBL5440980 | 0.78 | KDM1A (0.49) | FPR2FPR1F10F2HPGD | |
| SCHEMBL4691652 | 0.78 | FPR1 (0.48) | FPR2FPR1F10HPGDTSHR | |
| SCHEMBL13725967 | 0.76 | F10 (0.53) | F10LMNATSHRPOLB | |
| SCHEMBL4745979 | 0.76 | KDM1A (0.49) | FPR2FPR1F10HPGDTSHR | |
| SCHEMBL4745975 | 0.76 | NPC1 (0.48) | FPR2FPR1F10HPGDTSHR | |
| SCHEMBL76526 | 0.75 | RAB9A (0.62) | FPR2FPR1F10LMNATSHR | |
| SCHEMBL85562 | 0.75 | RAB9A (0.62) | FPR2FPR1F10LMNATSHR | |
| SCHEMBL5443184 | 0.75 | MAPT (0.57) | F10F2LMNAHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | FPR2 1695/4885FPR1 637/4885F10 5/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | FPR2 553/4885FPR1 300/4885F10 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.